ADZENYS ER

Peak

amphetamine

NDAORALSUSPENSION, EXTENDED RELEASE
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9

Mechanism of Action

non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal…

Clinical Trials (5)

NCT06721494Phase 2Recruiting

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

Started Feb 2026
NCT04132557N/ACompleted

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Started Oct 2019
430,000 enrolled
Attention Deficit Disorder With Hyperactivity
NCT05611385N/ACompleted

Amphetamine Induced Adult Respiratory Distress Syndrome

Started Jan 2019
49 enrolled
BurnsAcute Lung InjuryAcute Respiratory Distress Syndrome+1 more
NCT02959892Phase 1Completed

A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)

Started Dec 2016
12 enrolled
Healthy Volunteers
NCT01449565Phase 2Completed

Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)

Started Sep 2012
100 enrolled
Amphetamine-Related Disorders

Loss of Exclusivity

LOE Date
Jun 28, 2032
76 months away
Patent Expiry
Jun 28, 2032

Patent Records (3)

Patent #ExpiryTypeUse Code
8709491
Jun 28, 2032
Product
9017731
Jun 28, 2032
Product
9265737
Jun 28, 2032
Product